ZyVersa TherapeuticsZVSA
ZVSA
About: ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
Employees: 7
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
50% more funds holding
Funds holding: 4 [Q2] → 6 (+2) [Q3]
0.94% less ownership
Funds ownership: 1.23% [Q2] → 0.29% (-0.94%) [Q3]
81% less capital invested
Capital invested by funds: $38.7K [Q2] → $7.22K (-$31.5K) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for ZVSA.
Financial journalist opinion
Neutral
GlobeNewsWire
3 days ago
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Attend JPM's Healthcare Conference 2025 in San Francisco
ZyVersa looks forward to meeting with investors and potential collaborators at JPM 2025 to discuss our technology, pipeline, and development milestones.
Neutral
GlobeNewsWire
1 month ago
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
Stroke-related cardiovascular injury and dysfunction are induced by AIM2 inflammasome activation in the heart, which can be blocked by ZyVersa's IC 100.
Neutral
GlobeNewsWire
1 month ago
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
KEY BUSINESS HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease expected to begin Q1-2025. New Obesity, Metabolic & Inflammatory Disease Scientific Advisory Board (SAB) was formed in October 2024 to support development of Inflammasome ASC Inhibitor IC 100 for obesity with metabolic complications.
Neutral
GlobeNewsWire
1 month ago
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
During obesity, inflammasome-driven inflammation results in significant loss of pancreatic islet beta cell mass, severely impairing the insulin secreting capacity of the remaining beta cells. Preserving pancreatic islet beta cell function is key to prevention of insulin resistance and development of type 2 diabetes.
Neutral
GlobeNewsWire
1 month ago
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs
Obesity, due to its associated chronic, systemic inflammation, increases the risk for metabolic diseases, atherosclerosis, various malignant tumors, and numerous immune-mediated disorders. With weight loss, less inflammation is expected, but adipose tissue inflammation can persist long after weight loss.
Neutral
GlobeNewsWire
1 month ago
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases
Recent evidence links obesity-driven inflammation to diminished brain health and neurodegenerative diseases such as Alzheimer's and Parkinson's diseases The newly published data show that obesity leads to progressive brain inflammation in a mouse model, and that the proinflammatory processes worsen with prolonged obesity and with increased age This research supports our selection of obesity with associated comorbidities as the lead indication for Inflammasome ASC Inhibitor IC 100 IC 100 inhibits intra- and extracellular ASC and specks associated with multiple types of inflammasomes to attenuate damaging neurologic and systemic inflammation WESTON, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights data published in the peer-reviewed journal, Aging Cell, demonstrating that obesity in older adults or prolonged duration of obesity in the younger population resulted in inflammation and suppression of neurotrophic/neuroprotective factors in the brain, indicating that age and duration of obesity are critical risk factors for neurodegenerative diseases.
Neutral
GlobeNewsWire
2 months ago
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months
It is anticipated that Inflammasome ASC Inhibitor IC 100 will control chronic inflammation of obesity, attenuate comorbidities, and enhance weight loss.
Neutral
GlobeNewsWire
2 months ago
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors
WESTON, Fla., Oct. 15, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces that Stephen C.
Neutral
GlobeNewsWire
2 months ago
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications
New Scientific Advisory Board (SAB) comprised of five leading experts in the areas of obesity and metabolic diseases, and four leading inflammasome experts and inventors of IC 100 from University of Miami Miller School of Medicine who have provided ongoing scientific advisory support for IC 100 since its license. WESTON, Fla.
Neutral
GlobeNewsWire
4 months ago
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to begin H2-2024. Obesity with related metabolic complications selected as lead indication for Inflammasome ASC Inhibitor IC 100.
Charts implemented using Lightweight Charts™